The haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Wu, Xiaohua ^a   Chen, Shi ^a   He, Yongzheng ^a   Rhodes, Steven D ^a   Mohammad, Khalid S ^a   Li, Xiaohong ^a   Yang, Xianlin ^a   Jiang, Li ^a   Nalepa, Grzegorz ^a   Snider, Paige ^a   Robling, Alexander G ^a   Clapp, D Wade ^a   Conway, Simon J ^a   Guise, Theresa A ^a   Yang, Feng Chun ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; BONE REMODELING; BONE TURNOVER; CLINICAL FEATURE; CONTROLLED STUDY; FRACTURE HEALING; HAPLOINSUFFICIENCY; HEMATOPOIETIC CELL; MESENCHYMAL STEM CELL; MOUSE; NEUROFIBROMATOSIS; NONHUMAN; NULLIZYGOUS LOSS; OSTEOBLAST; OSTEOLYSIS; PATHOLOGIC FRACTURE; PROTEIN DEPLETION; STEM CELL; ZYGOSITY; ANIMAL; BONE DENSITY; CROSS BREEDING; CYTOLOGY; DISEASE MODEL; GENETICS; HEMATOPOIETIC STEM CELL; METABOLISM; MUTATION; TRANSGENIC MOUSE; TUMOR SUPPRESSOR GENE;

ANIMALIA; MURINAE; MUS;

BETA GALACTOSIDASE;

ANIMALS; BETA-GALACTOSIDASE; BONE DENSITY; CROSSES, GENETIC; DISEASE MODELS, ANIMAL; FRACTURE HEALING; GENES, NEUROFIBROMATOSIS 1; GERM-LINE MUTATION; HAPLOINSUFFICIENCY; HEMATOPOIETIC STEM CELLS; MESENCHYMAL STEM CELLS; MICE; MICE, TRANSGENIC; NEUROFIBROMATOSIS 1; OSTEOBLASTS;

EID: 80053311813     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024917     Document Type: Article

References (58)

1. Cecchini MG, Hofstetter W, Halasy J, Wetterwald A, Felix R, (1997) Role of CSF-1 in bone and bone marrow development. Mol Reprod Dev 46: 75-83; discussion 83-74.
2. Eriksen EF, (2010) Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord 11: 219-227.
3. Zhang J, Niu C, Ye L, Huang H, He X, et al. (2003) Identification of the haematopoietic stem cell niche and control of the niche size. Nature 425: 836-841.
4. Scadden DT, (2006) The stem-cell niche as an entity of action. Nature 441: 1075-1079.
5. Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, et al. (1990) Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 249: 181-186.
6. Atit RP, Mitchell K, Nguyen L, Warshawsky D, Ratner N, (2000) The neurofibromatosis type 1 (Nf1) tumor suppressor is a modifier of carcinogen-induced pigmentation and papilloma formation in C57BL/6 mice. J Invest Dermatol 114: 1093-1100.
7. Atit RP, Crowe MJ, Greenhalgh DG, Wenstrup RJ, Ratner N, (1999) The Nf1 tumor suppressor regulates mouse skin wound healing, fibroblast proliferation, and collagen deposited by fibroblasts. J Invest Dermatol 112: 835-842.
8. Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, et al. (2003) Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 63: 8573-8577.
9. Cichowski K, Jacks T, (2001) NF1 tumor suppressor gene function: narrowing the GAP. Cell 104: 593-604.
10. Sawada S, Florell S, Purandare SM, Ota M, Stephens K, et al. (1996) Identification of NF1 mutations in both alleles of a dermal neurofibroma. Nat Genet 14: 110-112.
11. Rasmussen SA, Overman J, Thomson SA, Colman SD, Abernathy CR, et al. (2000) Chromosome 17 loss-of-heterozygosity studies in benign and malignant tumors in neurofibromatosis type 1. Genes Chromosomes Cancer 28: 425-431.
12. Yang FC, Ingram DA, Chen S, Zhu Y, Yuan J, et al. (2008) Nf1-dependent tumors require a microenvironment containing Nf1+/- and c-kit-dependent bone marrow. Cell 135: 437-448.
13. Simmons GW, Pong WW, Emnett RJ, White CR, Gianino SM, et al. (2011) Neurofibromatosis-1 heterozygosity increases microglia in a spatially and temporally restricted pattern relevant to mouse optic glioma formation and growth. J Neuropathol Exp Neurol 70: 51-62.
14. Daginakatte GC, Gutmann DH, (2007) Neurofibromatosis-1 (Nf1) heterozygous brain microglia elaborate paracrine factors that promote Nf1-deficient astrocyte and glioma growth. Hum Mol Genet 16: 1098-1112.
15. Zhu Y, Ghosh P, Charnay P, Burns DK, Parada LF, (2002) Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science 296: 920-922.
16. Ajuebor MN, Hogaboam CM, Kunkel SL, Proudfoot AE, Wallace JL, (2001) The chemokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat. J Immunol 166: 552-558.
17. Rutkowski JL, Wu K, Gutmann DH, Boyer PJ, Legius E, (2000) Genetic and cellular defects contributing to benign tumor formation in neurofibromatosis type 1. Hum Mol Genet 9: 1059-1066.
18. Ingram DA, Yang FC, Travers JB, Wenning MJ, Hiatt K, et al. (2000) Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 191: 181-188.
19. Yang FC, Ingram DA, Chen S, Hingtgen CM, Ratner N, et al. (2003) Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest 112: 1851-1861.
20. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, et al. (2005) The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 102: 8573-8578.
21. Kuorilehto T, Kinnunen P, Nissinen M, Alanne M, Leskela HV, et al. (2006) Vasculopathy in two cases of NF1-related congenital pseudarthrosis. Pathol Res Pract 202: 687-690.
22. Kuorilehto T, Nissinen M, Koivunen J, Benson MD, Peltonen J, (2004) NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos. J Bone Miner Res 19: 983-989.
23. Kuorilehto T, Poyhonen M, Bloigu R, Heikkinen J, Vaananen K, et al. (2005) Decreased bone mineral density and content in neurofibromatosis type 1: lowest local values are located in the load-carrying parts of the body. Osteoporos Int 16: 928-936.
24. Lammert M, Kappler M, Mautner VF, Lammert K, Storkel S, et al. (2005) Decreased bone mineral density in patients with neurofibromatosis 1. Osteoporos Int 16: 1161-1166.
25. Jacques C, Dietemann JL, (2005) [Imaging features of neurofibromatosis type 1]. J Neuroradiol 32: 180-197.
26. Illes T, Halmai V, de Jonge T, Dubousset J, (2001) Decreased bone mineral density in neurofibromatosis-1 patients with spinal deformities. Osteoporos Int 12: 823-827.
27. Heuze Y, Piot B, Mercier J, (2002) [Difficult surgical management of facial neurofibromatosis type I or von Recklinghausen disease in children]. Rev Stomatol Chir Maxillofac 103: 105-113.
28. Stevenson DA, Moyer-Mileur LJ, Murray M, Slater H, Sheng X, et al. (2007) Bone mineral density in children and adolescents with neurofibromatosis type 1. J Pediatr 150: 83-88.
29. Stevenson DA, Zhou H, Ashrafi S, Messiaen LM, Carey JC, et al. (2006) Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet 79: 143-148.
30. Cohen MM Jr, (2006) The new bone biology: pathologic, molecular, and clinical correlates. Am J Med Genet A 140: 2646-2706.
31. Yang FC, Chen S, Robling AG, Yu X, Nebesio TD, et al. (2006) Hyperactivation of p21 and PI3K cooperate to alter murine and human neurofibromatosis type 1-haploinsufficient osteoclast functions. J Clin Invest 116: 2880-2891.
32. Kolanczyk M, Kossler N, Kuhnisch J, Lavitas L, Stricker S, et al. (2007) Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet 16: 874-886.
33. Elefteriou F, Benson MD, Sowa H, Starbuck M, Liu X, et al. (2006) ATF4 mediation of NF1 functions in osteoblast reveals a nutritional basis for congenital skeletal dysplasiae. Cell Metab 4: 441-451.
34. Wang W, Nyman J, Moss H, Gutierrez G, Mundy G, et al. (2010) Local low dose lovastatin delivery improves the bone healing defect caused by Nf1 loss-of-function in osteoblasts. J Bone Miner Res.
35. Kruzynska-Frejtag A, Wang J, Maeda M, Rogers R, Krug E, et al. (2004) Periostin is expressed within the developing teeth at the sites of epithelial-mesenchymal interaction. Dev Dyn 229: 857-868.
36. Yan W, Shao R, (2006) Transduction of a mesenchyme-specific gene periostin into 293T cells induces cell invasive activity through epithelial-mesenchymal transformation. J Biol Chem 281: 19700-19708.
37. Lindsley A, Snider P, Zhou H, Rogers R, Wang J, et al. (2007) Identification and characterization of a novel Schwann and outflow tract endocardial cushion lineage-restricted periostin enhancer. Dev Biol 307: 340-355.
38. Takeda N, Manabe I, Uchino Y, Eguchi K, Matsumoto S, et al. (2010) Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J Clin Invest 120: 254-265.
39. Rios H, Koushik SV, Wang H, Wang J, Zhou HM, et al. (2005) periostin null mice exhibit dwarfism, incisor enamel defects, and an early-onset periodontal disease-like phenotype. Mol Cell Biol 25: 11131-11144.
40. Zhang W, Rhodes SD, Zhao L, He Y, Zhang Y, et al. (2011) Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. Bone.
41. Warden SJ, Robling AG, Sanders MS, Bliziotes MM, Turner CH, (2005) Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146: 685-693.
42. Stevenson DA, Birch PH, Friedman JM, Viskochil DH, Balestrazzi P, et al. (1999) Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet 84: 413-419.
43. Dacquin R, Starbuck M, Schinke T, Karsenty G, (2002) Mouse alpha1(I)-collagen promoter is the best known promoter to drive efficient Cre recombinase expression in osteoblast. Dev Dyn 224: 245-251.
44. Marques P, Poutansant, Carbou, (1951) Osseous manifestations of neurofibromatosis (Recklinghausen's disease). J Radiol Electrol Arch Electr Medicale 32: 608-609.
45. Sbihi A, Balafrej A, Iraqui-Hamdouch N, Hamdouch M, Baroudi A, (1980) [Osseous manifestations of Recklinghausen's disease. The role of vertebral scalloping]. Maroc Med 2: 393-398.
46. Crawford AH Jr, Bagamery N, (1986) Osseous manifestations of neurofibromatosis in childhood. J Pediatr Orthop 6: 72-88.
47. Crawford AH, (1989) Pitfalls of spinal deformities associated with neurofibromatosis in children. Clin Orthop Relat Res pp. 29-42.
48. Yu X, Chen S, Potter OL, Murthy SM, Li J, et al. (2005) Neurofibromin and its inactivation of Ras are prerequisites for osteoblast functioning. Bone.
49. Wu X, Estwick SA, Chen S, Yu M, Ming W, et al. (2006) Neurofibromin plays a critical role in modulating osteoblast differentiation of mesenchymal stem/progenitor cells. Hum Mol Genet 15: 2837-2845.
50. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, et al. (1994) Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 7: 353-361.
51. Joseph NM, Mosher JT, Buchstaller J, Snider P, McKeever PE, et al. (2008) The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell 13: 129-140.
52. Liu F, Woitge HW, Braut A, Kronenberg MS, Lichtler AC, et al. (2004) Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. Int J Dev Biol 48: 645-653.
53. Munugalavadla V, Vemula S, Sims EC, Krishnan S, Chen S, et al. (2008) The p85alpha subunit of class IA phosphatidylinositol 3-kinase regulates the expression of multiple genes involved in osteoclast maturation and migration. Mol Cell Biol 28: 7182-7198.
54. O'Brien CA, Plotkin LI, Galli C, Goellner JJ, Gortazar AR, et al. (2008) Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 3: e2942.
55. Bonnarens F, Einhorn TA, (1984) Production of a standard closed fracture in laboratory animal bone. J Orthop Res 2: 97-101.
56. Komatsu DE, Mary MN, Schroeder RJ, Robling AG, Turner CH, et al. Modulation of Wnt signaling influences fracture repair. J Orthop Res 28: 928-936.
57. Warden SJ, Komatsu DE, Rydberg J, Bond JL, Hassett SM, (2009) Recombinant human parathyroid hormone (PTH 1-34) and low-intensity pulsed ultrasound have contrasting additive effects during fracture healing. Bone 44: 485-494.
58. Okabe M, Ikawa M, Kominami K, Nakanishi T, Nishimune Y, (1997) 'Green mice' as a source of ubiquitous green cells. FEBS Lett 407: 313-319.